Skip to main content

Advertisement

Log in

Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

SU5416 is a small, lipophilic synthetic molecule that selectively inhibits the tyrosine kinase activity of the VEGF receptor Flk-1/KDR. The role of this agent in brain tumors is currently being investigated. Pharmacokinetic studies of SU5416 have been performed in humans; however, there have been no studies of its penetration in the cerebrospinal fluid (CSF). We studied the pharmacokinetics of SU5416 in plasma and CSF after intravenous (i.v.) administration using a nonhuman primate model that is highly predictive of the CSF penetration in humans.

Experimental design

SU5416 (85 mg/m2, about 3.8 mg/kg) was administered i.v. over 20 min to four nonhuman primates. Serial plasma and CSF samples were obtained prior to, during, and after completion of the infusion for determination of SU5416 concentrations. SU5416 was measured in plasma and CSF using high-performance liquid chromatography (HPLC). Concentration-versus-time data were modeled using model-independent and model-dependent methods.

Results

Peak plasma concentrations ranged from 6.3 to 14.5 μM and the mean plasma AUC was 620±180 μM·min. Disappearance of SU5416 from the plasma was best described by a one-compartment model with a half-life of 39±2.9 min. The volume of distribution was 36±11 l/m2 and the clearance was 0.62±0.2 l/min per m2. SU4516 was not quantifiable in the CSF.

Conclusions

There is minimal penetration of SU5416 into the CSF after i.v. administration. The very low CNS exposure to SU5416 after i.v. dosing suggests that this agent is not optimal for the treatment of leptomeningeal tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.

Similar content being viewed by others

References

  1. Cropp G, Rosen L, Mulay M, Langecker P, Hannah A (1999) Pharmacokinetics and pharmacodynamics of SU5416 in a phase I, dose escalating trial in patients with advanced malignancies (abstract 619). Proc Am Soc Clin Oncol 18:161a

    Google Scholar 

  2. Donelli MG, Zucchetti M, D’Incalci M (1992) Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 30:251–260

    Google Scholar 

  3. Ellis LM, Takahashi Y, Liu W, Shaheen RM (2000) Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 5 [Suppl 1]:11

  4. Fong TAT, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99

    CAS  PubMed  Google Scholar 

  5. Kuenen BC, Rosen L, Smit EF, Parson MRN, Levi M, Ruijter R, Huisman H, Kedde MA, Noordhuis P, van der Vijgh WJF, Peters GJ, Cropp GF, Scigalla P, Hoekman K, Pinedo HM, Giaccone G (2002) Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 20:1657

    Article  CAS  PubMed  Google Scholar 

  6. McCully C, Balis F, Bacher J, Phillips J, Poplack D (1990) Rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab Anim Sci 40:520

    CAS  PubMed  Google Scholar 

  7. McMahon G (2000) VEGF receptor signaling in tumor angiogenesis. Oncologist 5 [Suppl 1]:3

  8. Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, Shaheen RM, Ellis LM, Weitman S, Shawver LK, Cherrington JM (2000) Development of SU5416, a selective small molecule inhibitor of the VEGF receptor tyrosine kinase activity, as an antiangiogenesis agent. Anticancer Drug Des 13:29

    Google Scholar 

  9. National Institutes of Health (1988) Guide for the care and use of laboratory animals. Department of Health, Education and Welfare (DHEW) publication (NIH) 85

  10. Poplack DG, Bleyer WA, Wood JH, Kostolich M, Savitch JL, Ommaya AK (1977) A primate model for study of methotrexate pharmacokinetics in the central nervous system. Cancer Res 37:1982

    CAS  PubMed  Google Scholar 

  11. Rosen L, Mulay M, Mayers A, Kabbinavar F, Rosen P, Cropp G, Hannah A (1999) Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies (abstract 618). Proc Am Soc Clin Oncol 18:161a

    Google Scholar 

  12. Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, McConkey DJ, McMahon G, Ellis LM (1999) Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 59:5412

    CAS  PubMed  Google Scholar 

  13. Shargel L, Yu ABC (eds) (1999) Applied biopharmaceutics and pharmacokinetics. McGraw-Hill, New York

  14. Sukbunterng J, Cropp G, Hannah A, Wagner GS, Shawver LK, Antonian L (2001) Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416. J Pharm Pharmacol 53:1629

    CAS  PubMed  Google Scholar 

Download references

Acknowledgement

This work was supported in part by UOI HD37242 and the Glaser Pediatric Research Network.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Renbarger, J., Aleksic, A., McGuffey, L. et al. Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates. Cancer Chemother Pharmacol 53, 39–42 (2004). https://doi.org/10.1007/s00280-003-0683-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-003-0683-z

Keywords

Navigation